|
Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury …
4-traders (press release) ‘Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney … |
Kelowna wins blood donation competition – Prince George Citizen
Kelowna wins blood donation competitionPrince George CitizenKelowna wins blood donation competition. Comments. Tweet. Kelowna wins blood donation competition. November 6, 2013. Citizen staff. Kelowna has reclaimed the Interior Drive for Life title from…
Why Charity is Right John Lorigan responds to the article "Why Charity is Wrong". – The University Times
The University Times |
Why Charity is Right John Lorigan responds to the article “Why Charity is Wrong”.
The University Times In the article, “Why charity is wrong”, the author mentions several things, including the VDP, global injustice, and how our political system is questionable. The fact that the world is unjust is … To run with the biological metaphor, what about … |
High-Risk Organs from Deceased Donors Safe When Screened – Renal Business Today
|
High-Risk Organs from Deceased Donors Safe When Screened
Renal Business Today ATLANTA—Approximately 10 percent of deceased donor kidneys are considered “high-risk” for infection (HIV, HCV, HBV) and disease transmission according to criteria set by the Centers for Disease Control and Prevention (CDC). But new research suggests … |
Research and Markets: Therapy Class Overview : Rituximab Biosimilar … – Business Wire (press release)
|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
Business Wire (press release) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
Research and Markets: Therapy Class Overview : Rituximab Biosimilar … – 4-traders (press release)
|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
4-traders (press release) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
Monoclonal Antibodies Market for Breast Cancer to More than Double by 2019 – PR Carbon (press release)
|
Monoclonal Antibodies Market for Breast Cancer to More than Double by 2019
PR Carbon (press release) FOR IMMEDIATE RELEASE, Illinois – United States – November 06, 2013 (PR Carbon): The market value for monoclonal antibodies (mAbs) in breast cancer treatment will experience a massive increase from $4.8 billion in 2012 to $10.9 billion in 2019, … |
Tale Of 10 Indians With Extraordinary Caliber – Siliconindia.com
Siliconindia.com |
Tale Of 10 Indians With Extraordinary Caliber
Siliconindia.com After his death, he has also donated parts of his organs like body and eyes to the Tirunelveli Medical College. The Government of India has applauded him as “The Best Librarian in India.” Rajarathinam has also been chosen as ‘one of the top ten … |
How DIY antibodies changed my life – The Canberra Times
|
How DIY antibodies changed my life
The Canberra Times The first Australian to treat immune system deficiency by self-administering concentrated antibodies has given the process the thumbs up. Waramanga’s Julie Cornwell-Kelly has made history by injecting a highly concentrated subcutaneous immunoglobulin … |
Airedale Hospital nurse's talk on organ donation – Ilkley Gazette
Ilkley Gazette |
Airedale Hospital nurse’s talk on organ donation
Ilkley Gazette The free talk, which will include information on the need for more people to join the organ-donation register, what happens at donation and how this changes the lives of recipients, will be given by specialist nurse for organ donation Rachel Wiseman. |